Daiichi Sankyo Company (4568) Aperçu de l'action
Daiichi Sankyo Company, Limited fabrique et vend des produits pharmaceutiques au Japon, en Amérique du Nord, en Europe et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 3/6 |
| Performances passées | 2/6 |
| Santé financière | 5/6 |
| Dividendes | 4/6 |
4568 Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Daiichi Sankyo Company, Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | JP¥2,779.50 |
| Plus haut sur 52 semaines | JP¥4,178.00 |
| Plus bas sur 52 semaines | JP¥2,390.00 |
| Bêta | -0.18 |
| Variation sur 1 mois | 3.73% |
| Variation sur 3 mois | 7.98% |
| Variation sur 1 an | -22.16% |
| Variation sur 3 ans | -34.55% |
| Variation sur 5 ans | 13.17% |
| Évolution depuis l'introduction en bourse | 260.19% |
Nouvelles et mises à jour récentes
Article d’analyse • Aug 10
Earnings Troubles May Signal Larger Issues for Daiichi Sankyo Company (TSE:4568) Shareholders
The market wasn't impressed with the soft earnings from Daiichi Sankyo Company, Limited ( TSE:4568 ) recently. We did...
Mise à jour du récit • Jul 31
4568: Oncology Approvals And Guidance Upgrades Will Drive Future Upside
Analysts have trimmed their price target for Daiichi Sankyo Company to around ¥4,146 from roughly ¥4,235, reflecting slightly softer assumptions for revenue growth, profit margins and future P/E multiples. What’s in the News for Daiichi Sankyo Company Daiichi Sankyo reported strong Q1 FY2026 growth, supported by new U.S. and international approvals for oncology drugs Enhertu and Datroway, and raised full year guidance for revenue and operating profit.Recent updates
Article d’analyse • Aug 10
Earnings Troubles May Signal Larger Issues for Daiichi Sankyo Company (TSE:4568) Shareholders
The market wasn't impressed with the soft earnings from Daiichi Sankyo Company, Limited ( TSE:4568 ) recently. We did...Mise à jour du récit • Jul 31
4568: Oncology Approvals And Guidance Upgrades Will Drive Future Upside
Analysts have trimmed their price target for Daiichi Sankyo Company to around ¥4,146 from roughly ¥4,235, reflecting slightly softer assumptions for revenue growth, profit margins and future P/E multiples. What’s in the News for Daiichi Sankyo Company Daiichi Sankyo reported strong Q1 FY2026 growth, supported by new U.S. and international approvals for oncology drugs Enhertu and Datroway, and raised full year guidance for revenue and operating profit.
Mise à jour du récit • Jul 14
4568: Tumor Agnostic Oncology Approvals In Europe Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Daiichi Sankyo Company, cutting the implied price target from ¥6,000 to ¥5,500 as they reassess expectations for revenue growth, profit margins, and the appropriate future P/E multiple. What's in the News AstraZeneca and Daiichi Sankyo secured European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.
Mise à jour du récit • Jun 30
4568: Broad Oncology Approvals Will Support A Balanced Future Market Rating
Analysts have reduced their Daiichi Sankyo Company price target from ¥2,846.48 to ¥2,750.00, citing updated assumptions that combine slightly higher expected revenue growth with a lower profit margin outlook and a higher future P/E multiple. What's in the News for Daiichi Sankyo Company AstraZeneca and Daiichi Sankyo received European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.Mise à jour du récit • Jun 16
4568: Oncology Biomarker Advances And Pipeline Approvals Will Drive Future Upside
Analysts have reduced their fair value estimate for Daiichi Sankyo Company from ¥4,736.88 to ¥4,234.71, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News Leica Biosystems expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and AI powered image analysis algorithm for the TROP2 Normalized Membrane Ratio biomarker in non small cell lung cancer, building on AstraZeneca’s computational pathology algorithm and Leica’s digital pathology platform for research use only.Mise à jour du récit • Jun 01
4568: Oncology Pipeline Progress And Measured Outlook Will Support Future Market Rating
Analysts have trimmed their price target for Daiichi Sankyo Company from about ¥3,065 to around ¥2,846. This reflects updated assumptions for slightly lower revenue growth, a reduced profit margin, a modestly higher discount rate, and a small adjustment to future P/E expectations.Article d’analyse • May 13
Daiichi Sankyo Company, Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
It's been a good week for Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders, because the company has just...Mise à jour du récit • May 11
4568: Oncology Regulatory Progress In Lung And Breast Cancer Will Drive Upside Potential
Analysts have kept Daiichi Sankyo Company's price target steady at ¥6,000, with small adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions shaping this unchanged view. What's in the News U.S. FDA accepted and granted Priority Review for the Biologics License Application for ifinatamab deruxtecan (I DXd) in extensive stage small cell lung cancer, with an FDA action date set for October 10, 2026.Mise à jour du récit • Apr 23
4568: Broad Oncology Pipeline And Buyback Progress Will Support A Higher Future Market Rating
Analysts have reduced their price target on Daiichi Sankyo Company from about ¥3,623 to roughly ¥3,065, citing updated assumptions that pair lower expected revenue growth with a slightly higher profit margin outlook and a more restrained future P/E of around 20x. What's in the News The share buyback program was completed, with 31,457,200 shares repurchased for ¥91,846.79 million, representing 1.7% of shares, under the authorization announced on April 25, 2025 (Key Developments).Mise à jour du récit • Apr 08
4568: Oncology Approvals And Priority Reviews Will Drive Future Upside Potential
Analysts have kept their ¥6,000 price target for Daiichi Sankyo unchanged, citing slightly adjusted views on revenue growth, profit margins, and future P/E assumptions as they refine their outlook on the company. What's in the News ENHERTU (trastuzumab deruxtecan) has been approved in Japan for HER2 positive advanced or recurrent solid cancers that are refractory or intolerant to standard treatments, supported by multiple phase 2 trials and accompanied by an interstitial lung disease warning in the prescribing information (Product related announcements).Mise à jour du récit • Mar 25
4568: Oncology Pipeline Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target on Daiichi Sankyo Company to ¥4,736.88 from ¥4,949.38, citing slightly lower assumed profit margins and a more conservative future P/E multiple, while keeping core growth assumptions broadly unchanged. What's in the News Daiichi Sankyo and AstraZeneca’s ENHERTU and DATROWAY oncology programs continue to move through global regulators, with multiple supplemental applications and Type II variations under review in the U.S., EU, Japan and China across breast, lung, gastric and other HER2 positive or TROP2 targeted cancer indications (regulatory filings).Mise à jour du récit • Mar 11
4568: Priority Oncology Filings And Reviews Will Drive Future Upside Potential
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥6,300 to ¥6,000, reflecting slightly lower modeled revenue growth, a modest adjustment to profit margins, and a small uptick in the discount rate and future P/E assumptions in their updated forecasts. What's in the News The U.S. FDA accepted and granted Priority Review to a supplemental Biologics License Application for ENHERTU for certain HER2 positive early breast cancer patients with residual invasive disease after neoadjuvant therapy, with a target decision date of July 7, 2026, under Project Orbis (Key Developments).Mise à jour du récit • Feb 25
4568: Future Breast Cancer Franchise Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥5,546 to ¥4,949, reflecting slightly lower forecasts for revenue growth, profit margins, and future P/E multiples. What's in the News The Board of Directors of IHH Healthcare Berhad reported that NTK has filed a petition with the Tokyo District Court to amend its claims against Daiichi Sankyo, seeking to adjust an existing injunctive request related to alleged obstruction of securities transactions and corporate actions involving Fortis and Malar, while keeping its previously stated monetary and reputational reliefs unchanged (Lawsuits & Legal Issues).Mise à jour du récit • Feb 10
4568: Broad Oncology Pipeline Progress Will Support A Higher Future Market Rating
Analysts have lowered their price target on Daiichi Sankyo Company from ¥4,500 to about ¥3,623, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News ENHERTU received multiple regulatory milestones, including approvals in China for HER2 positive metastatic gastric cancer and for HR positive, HER2 low or ultralow metastatic breast cancer, plus U.S. Breakthrough Therapy Designation in HER2 positive early breast cancer with high recurrence risk (company announcements).Article d’analyse • Feb 08
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend of ¥39.00 per share on the 24th...Article d’analyse • Feb 06
There May Be Underlying Issues With The Quality Of Daiichi Sankyo Company's (TSE:4568) Earnings
Daiichi Sankyo Company, Limited's ( TSE:4568 ) robust earnings report didn't manage to move the market for its stock...Article d’analyse • Feb 02
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders are probably feeling a little disappointed, since its shares...Mise à jour du récit • Jan 26
4568: Oncology Approvals And Trials Will Drive Future Upside Potential
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300. This reflects only small model adjustments to revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the shares.Article d’analyse • Jan 23
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...Mise à jour du récit • Jan 12
4568: Expanding Oncology Pipeline And Legal Win Will Drive Future Upside
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300, citing only small adjustments to revenue growth, profit margin, and future P/E expectations, which supports maintaining the prior valuation view. What's in the News ENHERTU received multiple regulatory approvals and designations across the U.S., China, Canada and Europe for various HER2 positive, HER2 low and HER2 ultralow breast cancer settings, including first line metastatic treatment and early stage high risk neoadjuvant use, backed by phase 3 data from DESTINY-Breast06, DESTINY-Breast09 and DESTINY-Breast11 (Key Developments).Article d’analyse • Jan 09
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) will pay a dividend of ¥39.00 on the 24th of June. The payment will take...Mise à jour du récit • Dec 27
4568: Oncology Pipeline Progress And IP Resolution Will Drive Future Upside
Analysts have nudged their price target for Daiichi Sankyo Company to ¥6,300, reflecting slightly stronger expectations for revenue growth to about 24.0 percent and a marginally higher profit margin near 21.0 percent, while maintaining a broadly similar outlook for valuation multiples. What's in the News ENHERTU received U.S. Breakthrough Therapy Designation for high risk HER2 positive early breast cancer with residual disease after neoadjuvant treatment, supported by positive phase 3 DESTINY Breast05 data and publication in The New England Journal of Medicine (Key Developments).Article d’analyse • Dec 25
Daiichi Sankyo Company (TSE:4568) Will Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...Mise à jour du récit • Dec 13
4568: Expanding Oncology Pipeline And Legal Clarity Will Drive Future Upside
Analysts have trimmed their price target on Daiichi Sankyo Company from ¥6,800 to ¥6,300. This reflects updated assumptions that pair slightly higher forecast revenue growth and profit margins with a more conservative valuation multiple and discount rate.Article d’analyse • Dec 11
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited's ( TSE:4568 ) investors are due to receive a payment of ¥39.00 per share on 24th of...Mise à jour du récit • Nov 25
4568: Future Oncology Pipeline Success Will Drive Further Upside For Shares
Analysts have raised their price target for Daiichi Sankyo Company from ¥5,517.06 to ¥5,546.47, citing slightly higher revenue growth expectations. This increase offsets a modest rise in the discount rate and a marginal dip in projected profit margins.Article d’analyse • Nov 04
Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) defied analyst predictions to release its half-yearly results, which were...Mise à jour du récit • Oct 22
Analysts Lower Daiichi Sankyo Price Target as New Cancer Data Drives Valuation Tweaks
Narrative Update on Daiichi Sankyo Company: Analyst Price Target Adjustment Analysts have slightly reduced their fair value estimate for Daiichi Sankyo Company from ¥5,528.82 to ¥5,517.06. This adjustment reflects moderately revised assumptions around revenue growth and future earnings expectations.Mise à jour du récit • Oct 08
Global Aging And ADC Pipelines Will Expand Oncology Markets
Analysts have slightly raised their price target for Daiichi Sankyo Company from ¥5,459 to ¥5,529, attributing the adjustment to improved profit margin expectations. This change comes even as revenue growth projections were moderated.Article d’analyse • Sep 21
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be paying its dividend of ¥39.00...Article d’analyse • Sep 05
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...Mise à jour du récit • Sep 04
Global Aging And ADC Pipelines Will Expand Oncology Markets
With Daiichi Sankyo's net profit margin and future P/E multiples both effectively unchanged, analysts have maintained their consensus price target at ¥5459. What's in the News DATROWAY (datopotamab deruxtecan) approved in China for HR positive, HER2 negative breast cancer after prior endocrine and chemotherapy, jointly developed with AstraZeneca.Article d’analyse • Aug 22
Daiichi Sankyo Company (TSE:4568) Has Announced That It Will Be Increasing Its Dividend To ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...Rendement pour les actionnaires
| 4568 | JP Pharmaceuticals | JP Marché | |
|---|---|---|---|
| 7D | 4.5% | 6.3% | 1.9% |
| 1Y | -22.2% | 15.4% | 32.7% |
Rendement vs Industrie: 4568 a sous-performé le secteur JP Pharmaceuticals qui a rapporté 15.4 % au cours de l'année écoulée.
Rendement vs marché: 4568 a sous-performé le marché JP qui a rapporté 32.7 % au cours de l'année écoulée.
Volatilité des prix
| 4568 volatility | |
|---|---|
| 4568 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in JP Market | 9.4% |
| 10% least volatile stocks in JP Market | 2.2% |
Cours de l'action stable: 4568 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché JP.
Volatilité au fil du temps: La volatilité hebdomadaire de 4568 ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1899 | 20,171 | Hiroyuki Okuzawa | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited fabrique et vend des produits pharmaceutiques au Japon, en Amérique du Nord, en Europe et dans le monde entier. La société propose Enhertu pour traiter les patients atteints de cancer du sein HER2 positif et faible, d'adénocarcinome gastrique ou de la jonction gastro-œsophagienne HER2 positif et de tumeurs solides HER2 positives ; Turalio, une petite molécule orale qui cible le récepteur du facteur 1 de stimulation des colonies, le récepteur tyrosine kinase du proto-oncogène KIT et la tyrosine kinase 3 de type FMS portant une mutation de duplication en tandem interne ; Vanflyta, un inhibiteur de FLT3 pour le traitement des patients adultes atteints de leucémie myéloïde aiguë ; et Injectafer, une injection de carboxymaltose ferrique pour le traitement de la carence en fer. Elle propose également Liziana et Savaysa, des inhibiteurs directs du facteur Xa ; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar et Sevikar HCT, des agents antihypertenseurs ; Nilemdo, un traitement oral qui réduit le cholestérol ; Nustendi, un comprimé à dose fixe associant l'acide bémpédoïque et l'ézétimibe pour réduire le cholestérol ; et Efient, un antiagrégant plaquettaire.
Daiichi Sankyo Company, Limited Résumé des fondamentaux
| 4568 statistiques fondamentales | |
|---|---|
| Capitalisation boursière | JP¥5.11t |
| Bénéfices(TTM) | JP¥243.01b |
| Recettes(TTM) | JP¥2.22t |
20.8x
Ratio P/E2.3x
Ratio P/SLe site 4568 est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| 4568 compte de résultat (TTM) | |
|---|---|
| Recettes | JP¥2.22t |
| Coût des recettes | JP¥700.99b |
| Marge brute | JP¥1.52t |
| Autres dépenses | JP¥1.28t |
| Les revenus | JP¥243.01b |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 133.49 |
| Marge brute | 68.47% |
| Marge bénéficiaire nette | 10.93% |
| Ratio dettes/capitaux propres | 29.4% |
Quelles ont été les performances à long terme de 4568?
Voir les performances historiques et les comparaisonsDividendes
3.6%
Rendement actuel des dividendes59%
Ratio de distributionLe site 4568 verse-t-il des dividendes fiables ?
Voir 4568 l'historique des dividendes et les indices de référence| Daiichi Sankyo Company dates des dividendes | |
|---|---|
| Date ex-dividende | Sep 29 2026 |
| Date de paiement du dividende | Dec 10 2026 |
| Jours jusqu'au dividende Ex | 47 days |
| Jours jusqu'à la date de paiement du dividende | 119 days |
Le site 4568 verse-t-il des dividendes fiables ?
Voir 4568 l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/13 08:49 |
| Cours de l'action en fin de journée | 2026/08/13 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Daiichi Sankyo Company, Limited est couverte par 28 analystes. 17 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |